GlassScriptPhysician profile
Katie M White
NPI 1386089357
$10,169.75
in general payments reported to CMS, 2019-2025
28 companies · $2,619 in 2025
The $2,619 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.96 · 2022: $1,900 · 2023: $2,667 · 2024: $2,946 · 2025: $2,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,917 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,916.91 |
| Education | $314.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,140.97 | 2021-2025 | |
| Genzyme Corporation | $1,042.47 | 2022-2025 | |
| Lilly USA, LLC | $983.84 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $945.20 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $797.77 | 2022-2025 | Dupixent, Libtayo |
| Ucb, INC. | $665.37 | 2022-2025 | Bimzelx |
| Janssen Biotech, INC. | $655.68 | 2022-2025 | Tremfya |
| Pfizer INC. | $593.19 | 2022-2025 | |
| Leo Pharma INC. | $468.50 | 2022-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $454.82 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $444.65 | 2022-2025 | Winlevi |
| E.R. Squibb & Sons, L.L.C. | $410.99 | 2022-2024 | Sotyktu |
| Incyte Corporation | $396.60 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $254.25 | 2024-2025 | Nemluvio |
| Amgen INC. | $226.27 | 2023-2025 | Otezla, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $183.65 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $140.97 | 2023-2025 | Siliq, Cabtreo, Jublia |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $77.96 | 2025 | Dupixent |
| Almirall LLC | $39.53 | 2023 | Seysara |
| Glaxosmithkline, LLC. | $38.33 | 2021-2022 | |
| Organon LLC | $24.61 | 2025 | Vtama |
| Celltrion USA INC. | $20.33 | 2023 | Yuflyma |
| Kaleo, INC. | $19.86 | 2022 | |
| Organogenesis INC. | $19.28 | 2023 | Puraply |
| Verrica Pharmaceuticals INC. | $17.15 | 2025 | Ycanth |
| Sandoz INC. | $15.87 | 2024 | Hyrimoz |
| Journey Medical Corporation | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.